vs
bioAffinity Technologies, Inc.（BIAF）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是bioAffinity Technologies, Inc.的444.8倍（$708.5M vs $1.6M）。Medpace Holdings, Inc.净利率更高（19.1% vs -197.0%，领先216.1%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -27.8%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-2.6M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -18.6%）
bioAffinity Technologies是一家处于临床阶段的生物技术企业，专注于研发可用于癌症、呼吸系统疾病早期检测的非侵入性体外诊断产品，面向全球医疗市场，致力于提供高准确率的便捷诊断方案，改善患者诊疗体验与预后效果。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
BIAF vs MEDP — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6M | $708.5M |
| 净利润 | $-3.1M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | -196.9% | 21.6% |
| 净利率 | -197.0% | 19.1% |
| 营收同比 | -27.8% | 32.0% |
| 净利润同比 | -5.7% | 15.5% |
| 每股收益（稀释后） | $-3.59 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $1.6M | $708.5M | ||
| Q3 25 | $1.4M | $659.9M | ||
| Q2 25 | $1.3M | $603.3M | ||
| Q1 25 | $1.9M | $558.6M | ||
| Q4 24 | $2.2M | $536.6M | ||
| Q3 24 | $2.4M | $533.3M | ||
| Q2 24 | $2.4M | $528.1M | ||
| Q1 24 | $2.4M | $511.0M |
| Q4 25 | $-3.1M | $135.1M | ||
| Q3 25 | $-5.1M | $111.1M | ||
| Q2 25 | $-4.1M | $90.3M | ||
| Q1 25 | $-2.7M | $114.6M | ||
| Q4 24 | $-3.0M | $117.0M | ||
| Q3 24 | $-2.0M | $96.4M | ||
| Q2 24 | $-2.1M | $88.4M | ||
| Q1 24 | $-2.0M | $102.6M |
| Q4 25 | -196.9% | 21.6% | ||
| Q3 25 | -158.6% | 21.5% | ||
| Q2 25 | -198.2% | 20.9% | ||
| Q1 25 | -141.7% | 20.3% | ||
| Q4 24 | -133.5% | 23.4% | ||
| Q3 24 | -84.0% | 21.1% | ||
| Q2 24 | -87.1% | 19.9% | ||
| Q1 24 | -80.8% | 20.4% |
| Q4 25 | -197.0% | 19.1% | ||
| Q3 25 | -349.3% | 16.8% | ||
| Q2 25 | -319.9% | 15.0% | ||
| Q1 25 | -143.5% | 20.5% | ||
| Q4 24 | -134.4% | 21.8% | ||
| Q3 24 | -85.1% | 18.1% | ||
| Q2 24 | -88.0% | 16.7% | ||
| Q1 24 | -81.5% | 20.1% |
| Q4 25 | $-3.59 | $4.65 | ||
| Q3 25 | $-4.74 | $3.86 | ||
| Q2 25 | $-0.17 | $3.10 | ||
| Q1 25 | $-0.16 | $3.67 | ||
| Q4 24 | $-17.27 | $3.67 | ||
| Q3 24 | $-4.84 | $3.01 | ||
| Q2 24 | $-0.19 | $2.75 | ||
| Q1 24 | $-0.20 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3M | $459.1M |
| 总资产 | $11.0M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $6.4M | $497.0M | ||
| Q3 25 | $7.7M | $285.4M | ||
| Q2 25 | $802.8K | $46.3M | ||
| Q1 25 | $444.7K | $441.4M | ||
| Q4 24 | $1.1M | $669.4M | ||
| Q3 24 | $756.6K | $656.9M | ||
| Q2 24 | $801.3K | $510.9M | ||
| Q1 24 | $2.5M | $407.0M |
| Q4 25 | $7.3M | $459.1M | ||
| Q3 25 | $8.9M | $293.6M | ||
| Q2 25 | $-2.1M | $172.4M | ||
| Q1 25 | $1.4M | $593.6M | ||
| Q4 24 | $2.6M | $825.5M | ||
| Q3 24 | $3.1M | $881.4M | ||
| Q2 24 | $3.4M | $763.6M | ||
| Q1 24 | $5.3M | $671.5M |
| Q4 25 | $11.0M | $2.0B | ||
| Q3 25 | $11.5M | $1.8B | ||
| Q2 25 | $4.8M | $1.6B | ||
| Q1 25 | $5.5M | $1.9B | ||
| Q4 24 | $6.5M | $2.1B | ||
| Q3 24 | $6.6M | $2.1B | ||
| Q2 24 | $6.7M | $1.9B | ||
| Q1 24 | $8.0M | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.6M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.6M | $188.1M |
| 自由现金流率自由现金流/营收 | -160.7% | 26.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | $-9.4M | $681.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-2.6M | $192.7M | ||
| Q3 25 | $-2.5M | $246.2M | ||
| Q2 25 | $-2.6M | $148.5M | ||
| Q1 25 | $-1.6M | $125.8M | ||
| Q4 24 | $-1.7M | $190.7M | ||
| Q3 24 | $-1.7M | $149.1M | ||
| Q2 24 | $-1.5M | $116.4M | ||
| Q1 24 | $-2.3M | $152.7M |
| Q4 25 | $-2.6M | $188.1M | ||
| Q3 25 | $-2.5M | $235.5M | ||
| Q2 25 | $-2.7M | $142.4M | ||
| Q1 25 | $-1.7M | $115.8M | ||
| Q4 24 | $-1.7M | $183.0M | ||
| Q3 24 | $-1.7M | $138.5M | ||
| Q2 24 | $-1.6M | $103.5M | ||
| Q1 24 | $-2.4M | $147.2M |
| Q4 25 | -160.7% | 26.6% | ||
| Q3 25 | -171.8% | 35.7% | ||
| Q2 25 | -209.6% | 23.6% | ||
| Q1 25 | -91.3% | 20.7% | ||
| Q4 24 | -76.0% | 34.1% | ||
| Q3 24 | -73.1% | 26.0% | ||
| Q2 24 | -65.1% | 19.6% | ||
| Q1 24 | -99.2% | 28.8% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.7% | 1.8% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.4% | 2.0% | ||
| Q2 24 | 1.2% | 2.4% | ||
| Q1 24 | 1.7% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIAF
暂无分部数据
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
